Rhythm reports positive Phase 3 data for hypothalamic obesity drug
#Rhythm Pharmaceuticals #setmelanotide #TRANSCEND trial #hypothalamic obesity #BMI reduction #Phase 3 trial #pharmaceuticals #acquired obesity
📌 Key Takeaways
- Rhythm Pharmaceuticals reported positive Phase 3 trial results for setmelanotide.
- The drug targets acquired hypothalamic obesity.
- The TRANSCEND trial showed an 18.8% placebo-adjusted BMI reduction at 52 weeks.
- The trial was conducted over a period of 52 weeks.
📖 Full Retelling
Boston-based Rhythm Pharmaceuticals announced positive Phase 3 trial data for its drug, setmelanotide, targeting acquired hypothalamic obesity. The TRANSCEND trial, conducted over 52 weeks, demonstrated an 18.8% placebo-adjusted reduction in Body Mass Index (BMI). This data indicates the potential efficacy of setmelanotide in treating this condition.
🏷️ Themes
Pharmaceutical research, Obesity treatment, Clinical trials, Endocrinology
Entity Intersection Graph
No entity connections available yet for this article.
Original Source
BOSTON - Rhythm Pharmaceuticals (NASDAQ:RYTM) announced additional data from its Phase 3 TRANSCEND trial evaluating setmelanotide for acquired hypothalamic obesity, showing an 18.8% placebo-adjusted difference in BMI reduction at 52 weeks.
Read full article at source